The R&D pipeline for new drugs has changed considerably over the past decade. 

Once dominated by big pharma and small molecules, today’s pipeline is increasingly populated with small and emerging biotech companies developing large molecules, or biologics, which now make up nearly 40% of the active R&D pipeline globally. As scientific advancement in biopharmaceuticals continues to rise, so will the market. The global biological market size is expected to reach $750 billion in 2028 — up from the $285 billion biologics revenues seen in 2020. This rapid and continual growth has created a demand for therapeutics, expanding indications for biologics, and the growing portfolios of biologics. 

Biologics are mainly used for treatment of conditions such as cancer, infectious, ophthalmic, anemia and autoimmune diseases and the current success rate is encouraging bio-pharmaceutical players to invest in research and development of biologics on large scale. While these projections are good news for patients and for makers of bio therapies, growth always comes with new challenges. In this case, the industry must learn how to deploy efficient, flexible-modular manufacturing technologies that can respond to upstream and downstream variables. These variables include the proliferation of new biologics, rapid shifts in volumetric requirements, and improvements in cell and bacterial culture strategies. 

MPTxpress development comprises the activites that help create a series of steps of steps to produce a biomolecule – a antibody fragment, recombinant protein, recombinant enzyme, plasmid DNA, Viral Vector, or other product that comes from a biological origin.

MPTxpress process is well positioned to offer tangible benefits such as modular batch size, lower operating cost, and faster turnaround and reduced capital investment. We draw on our manufacturing and quality expertise to design Bioprocesses that include optimization and validation of cell line development, upstream and downstream steps processes at scale. 

MPTxpress enables us to produce biologics on a rapid, reliable and repeatable scale-up.